Progesterone and estrogen are important drivers of breast cancer proliferation. Herein, we probed estrogen receptor-a (ER) and progesterone receptor (PR) cross-talk in breast cancer models. Stable expression of PR-B in PR-low/ER þ MCF7 cells increased cellular sensitivity to estradiol and insulin-like growth factor 1 (IGF1), as measured in growth assays performed in the absence of exogenous progestin; similar results were obtained in PR-null/ER þ T47D cells stably expressing PR-B. Genome-wide microarray analyses revealed that unliganded PR-B induced robust expression of a subset of estradiol-responsive ER target genes, including cathepsin-D (CTSD). Estradiol-treated MCF7 cells stably expressing PR-B exhibited enhanced ER Ser167 phosphorylation and recruitment of ER, PR and the proline-, glutamate-and leucine-rich protein 1 (PELP1) to an estrogen response element in the CTSD distal promoter; this complex co-immunoprecipitated with IGF1 receptor (IGFR1) in whole-cell lysates. Importantly, ER/PR/PELP1 complexes were also detected in human breast cancer samples. Inhibition of IGF1R or phosphoinositide 3-kinase blocked PR-B-dependent CTSD mRNA upregulation in response to estradiol. Similarly, inhibition of IGF1R or PR significantly reduced ER recruitment to the CTSD promoter. Stable knockdown of endogenous PR or onapristone treatment of multiple unmodified breast cancer cell lines blocked estradiol-mediated CTSD induction, inhibited growth in soft agar and partially restored tamoxifen sensitivity of resistant cells. Further, combination treatment of breast cancer cells with both onapristone and IGF1R tyrosine kinase inhibitor AEW541 was more effective than either agent alone. In summary, unliganded PR-B enhanced proliferative responses to estradiol and IGF1 via scaffolding of ER-a/PELP1/IGF1R-containing complexes. Our data provide a strong rationale for targeting PR in combination with ER and IGF1R in patients with luminal breast cancer.
INTRODUCTION
Approximately 70% of newly diagnosed breast cancers are luminal breast cancers that are positive for estrogen receptor-a (ER) and progesterone receptor (PR) expression. 1 Although ER-targeted therapies are relatively successful in treating ER þ tumors, primary endocrine resistance occurs in up to a third of all breast cancers. 2 Mechanisms of resistance to ER-targeted therapies are widely studied and include upregulation of growth factor pathways and increased ER cytoplasmic signaling, in addition to altered ER target gene profiles, enhanced ER phosphorylation and deregulation of ER pathway components. 3, 4 For example, the proline-, glutamateand leucine-rich protein 1 (PELP1), a growth factor receptor adaptor molecule and ER coactivator, is frequently upregulated in endocrineresistant tumors. 5 Endocrine-resistant tumors are characterized by increased aggressiveness and metastatic potential. Patients with recurrent endocrine-resistant tumors are generally treated with systemic chemotherapy.
PR expression in breast cancer predicts response to ER-targeted therapies, partly because ER regulates PR expression. 3 In addition, both ER and PR share similar signaling pathways 6 and exhibit substantial overlap in their transcriptomes. 7 Recent mechanistic studies by our group and others have shown that PR is capable of driving breast cancer progression in both the absence and presence of progestin. 8 Ligand-independent PR actions include scaffolding of growth factor pathways to enhance kinase signaling 9 and activation of progrowth and prosurvival transcriptional programs in breast cancer cells. [10] [11] [12] In vitro models of aromatase inhibitor-resistant breast cancer cells demonstrated sensitivity to the PR antagonist, CDB-2914, which inhibited cell cycle progression. 13 Recently, ER has been shown to cooperate with PR in response to progestins. 14 Additional evidence demonstrated that cells in the normal adult mammary gland 15 and in breast tumors 16 contain cell populations that express ER only, PR only, both receptors or neither. A small population of SR þ (steroid receptor) cells in the normal mammary gland have been shown to secrete paracrine factors and thereby provide potent proliferative signals to adjacent SR À cells. 17 Indeed, estradiol (E2) has been shown to drive the proliferative actions of PR-B, an ER target gene that is required for mammary gland alveologenesis. 17 In addition, PR-B has been shown to induce breast cancer cell growth in soft agar assays, whereas PR-A does not. 18 These data provide a strong rationale for the study of ER actions independently of PR and in conjunction with PR to better understand how these SRs cooperate to modulate hormone responsiveness in normal and breast cancer tissues. Herein, we hypothesized that PR-B þ /ER þ breast cancer cells have a heightened sensitivity to estrogen because of direct molecular cross-talk between ER and PR-B. This heightened sensitivity represents a potential mechanism by which resistance to endocrine therapy can develop.
RESULTS

PR-B enhances breast cancer cell proliferation in response to estradiol and IGF1
To address the question of whether ER and PR-B, the mitogenic PR isoform in the breast, work in concert to enhance estradiol sensitivity in breast cancer cells, we utilized the traditionally SR þ breast cancer cell model, MCF7. Beginning with a naturally occurring ER þ /PR-low variant of MCF7 cells, 19 we stably re-expressed either PR-B (pSG5-PR-B) or a vector (pSG5) control ( Figure 1a ). Cells expressing PR-B or vector-matched controls were then subjected to MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) proliferation assays and grown in soft agar. Notably, MCF7 cells lacking PR-B but containing abundant ER-a were not significantly responsive to estradiol as measured by MTT assays; however, MCF7 cells expressing PR-B displayed significantly heightened proliferation in response to estradiol (Supplementary Figure S1A ). PR-B-null MCF7 cells (empty vector) displayed a slight increase in colony formation in response to estradiol. MCF7 cells stably expressing PR-B displayed increased anchorage-independent growth in response to estradiol relative to PR-null controls (Figures 1b and c). Similar results were observed in ER þ /PR-null T47D cells stably expressing PR-B relative to vector controls (Supplementary Figure S1 and Figure 1c ); interestingly, these cells were also more responsive to IGF1 treatment, a growth factor receptor pathway known to cross-talk extensively with ER signaling. 20 In addition, we examined the estradiol-induced growth of unmodified MCF7L and BT474 breast cancer cell lines after treatment with the type II anti-PR drug onapristone. MCF7L cells are ER þ /PR þ and express abundant levels of PR-A and PR-B (Figure 1e ). BT474 cells are ER þ /PR þ /HER2 þ and are considered relatively aggressive but still highly responsive to estradiol. Onapristone partially blocked (41%) estradiol-induced soft agar growth of MCF7L cells ( Figure 1d ) and markedly inhibited (63%) estradiol-driven soft agar growth of BT474 cells (Figure 1e ). Notably, onapristone treatment did not alter ER expression levels in either cell line ( Figure 1f ).
To complement these studies, we performed gene-silencing experiments in MCF7L cells that express abundant levels of PR-A and PR-B. ER þ /PR þ MCF7L cells were stably transfected with short hairpin (sh) RNAs targeting green fluorescent protein (control; sh green fluorescent protein) or PRs (shPR). Total PR mRNA (quantitative real-time polymerase chain reaction (qRT-PCR)) and PR protein (western blot (WB)) levels were assessed to confirm PR Figure S2A and not shown). ER expression remained relatively unchanged upon PR knockdown (Supplementary Figure S2A ). Soft agar assays demonstrated that cells expressing control shRNA exhibited basal colony formation that was significantly enhanced by estradiol treatment. In contrast, estradiol-induced soft agar colony formation was significantly blunted by shPR (Supplementary Figure S2B ) and partially blocked by onapristone ( Figure 1d ). Taken together, our data demonstrate a novel ligand-independent PR function in ER þ breast cancer cells, in which PR-B confers heightened responsiveness to estradiol and IGF1.
Estradiol-treated PR-B þ /ER þ breast cancer cells express a distinct gene signature associated with tumor progression To determine whether unliganded PR-B participates in ER-dependent transcriptional responses, we performed gene array analyses to measure changes in the ER transcriptome. Serum-starved MCF7 cells stably expressing either vector or PR-B were treated with estradiol (6 h), and mRNA was harvested for gene expression analyses. Unsupervised clustering of differentially regulated genes was visualized by heat map. As predicted, 10,12 PR-B expression alone profoundly altered hormone-independent (basal) gene expression ( Figure 2a , lanes 1 and 3). Estradiol-stimulated gene expression profiles revealed 40 genes that were upregulated (42fold, Po0.001) and 49 genes that were downregulated (o2-fold, Po0.001) (Figure 2a , lanes 2 and 4) in PR-B-expressing cells compared with PR-null vector-matched controls ( Supplementary   Table S1 ). Ingenuity Pathway Analysis revealed that the biological processes significantly associated with this PR-B-dependent, estradiol-induced gene signature included cancer, cell cycle, reproductive system disease, cellular movement, cell growth and proliferation, and cell death and survival (Supplementary Figure  S3A ). Furthermore, Gene Set Enrichment Analysis showed that estradiol-induced genes in PR-B þ MCF7 cells were significantly (false discovery rate o0.05) associated with genes upregulated in the luminal-B subtype of breast cancer 21 (Supplementary Figure  S3B) , two independent tamoxifen-resistant signatures 22, 23 and ESR1-positive breast tumors relative to ESR1-negative tumors. 24 Notably, luminal B breast cancers are more likely to become endocrine resistant. 25 These data indicate that PR-B and ER cooperate in the regulation of estradiol-induced gene expression programs associated with breast tumor progression.
Known ER target genes among the 40 genes upregulated in PR-B þ /ER þ MCF7 cells relative to PR-null/ER þ vector-matched controls were examined by qRT-PCR. PR-B expression significantly enhanced estradiol responsiveness to SLC7A5 (Figure 2b , upper panel), a gene known to be regulated by ER and IGF1. 26 Notably, a query of TCGA (The Cancer Genome Atlas) breast cancer data 27 found that SLC7A5 mRNA was expressed at higher levels in invasive breast carcinoma than in normal mammary tissue ( Figure 2b ), lower panel). In addition, PR-B expression significantly increased estradiol sensitivity to induced ER target genes WISP2 and PTGES ( Figure 2c ). Similar to PR-dependent but estradiolinduced genes, numerous genes were also downregulated by Notably, PR-B expression exclusively enhanced estradiol sensitivity for the classical ER-target gene cathepsin-D (CTSD) (Figure 3a ). Estradiol-induced CTSD expression in PR-B þ MCF7 cells was not significantly affected by the addition of progestin or IGF1 ( Supplementary Figures S4A and S4B ). The expression of TFF1 (pS2), another well-characterized ER target gene, was not affected by PR-B expression ( Figure 3a ). As expected, expression of SGK, a classical PR target gene, was increased in PR-B þ MCF7 cells treated with the synthetic progestin, R5020 (Figure 3a ). Analysis of the TCGA breast cancer data set revealed that CTSD expression was also significantly higher in invasive breast cancers than in normal tissues ( Figure 3b ). Interestingly, analysis of PR and CTSD mRNA expression demonstrated a tendency toward co-occurrence in invasive breast carcinoma in the TCGA data set, whereas PR and TFF1 expression were not associated. These data demonstrate that PR-B cooperates with ER to drive the expression of a subset of ER target genes.
PR-A and PR-B isoforms are coexpressed in normal and neoplastic cells; however, the ratio of PR-A to PR-B frequently varies among breast tumors. 28 To determine whether PR-A also cooperates with ER to drive CTSD expression, we utilized previously characterized PR-null T47D cells stably expressing either PR-A or PR-B 11 (Supplementary Figure S5A ). Similar to our results in MCF7 cells, PR-null/ER þ T47D cells did not induce CTSD expression in response to estradiol, whereas PR-B þ /ER þ T47D cells did induce CTSD expression ( Figure 4a ). In contrast to PR-Bexpressing cells, PR-A þ /ER þ T47D cells failed to increase the expression of CTSD in response to estradiol (Supplementary Figure  S5B) . These data suggest that PR-B is the primary mediator of cross-talk with ER in the upregulation of CTSD.
PR DNA-binding domain is essential for CTSD expression CTSD is widely used as a measure of estradiol responsiveness in breast cancer models. 29 We therefore focused on the regulation of this gene as a model for probing mechanistic interactions between ER and PR-B. To test the requirement for the PR DNAbinding domain in estradiol-induced CTSD regulation, we again utilized PR-null T47D cells engineered to stably express either wild-type (wt) PR-B or a DNA-binding domain mutant of PR-B (DBM PR-B). 18 Importantly, ER protein levels in T47D cells stably expressing either wt or DBM PR-B cells were comparable; however, PR-B protein levels were higher in T47D cells expressing DBM PR-B (Figure 4b , inset), perhaps due to deficient turnover of this mutant protein. T47D cells expressing DBM PR-B failed to induce CTSD upon estradiol stimulation relative to the significant response observed in T47D cells expressing wt PR-B (Figure 4b ). The classical ER target gene, TFF1, was significantly upregulated in both cell lines upon estradiol treatment (not shown). These data show that the PR DNA-binding domain is required for ER/PR-B coregulation of CTSD expression.
PR-B and ER are recruited to the CTSD promoter in response to estradiol ER binds to both proximal 30 and distal 29 sites in the CTSD promoter in response to estradiol. We focused on the distal ER binding site as the primary site for estradiol-mediated CTSD upregulation. 29 Chromatin immunoprecipitation (ChIP) assays were performed on MCF7 cells expressing PR-B or vector-matched controls. Cells were treated (1 h) with vehicle or estradiol before assessment of ER recruitment to the CTSD distal promoter. Interestingly, ER binding to the distal region of the CTSD promoter was negligible in PR-null, vector-matched control cells, whereas it was robust in PR-Bexpressing cells treated with estradiol ( Figure 4c ). Previously published estradiol-responsive elements in the promoter region of a control gene (TFF1) were also examined for ER binding under these conditions; 30 ER was equally recruited to the TFF1 promoter upon estradiol stimulation in vector and PR-B-expressing MCF7 cells (not shown).
To determine whether ER/PR-B complexes drive estradioldependent transcription of CTSD, we again performed ChIP assays in PR-B-expressing MCF7 cells treated with vehicle or estradiol (40 min) using antibodies specific for either ER or PR. As above, ER recruitment was again observed upon estradiol stimulation of PR-B-containing cells (Figure 4d ). In addition, PR recruitment to the CTSD promoter was detected after estradiol stimulation of MCF7 cells (Figure 4d ), although at lower levels than ER recruitment. Similar results were observed in T47D cells stably expressing PR-B (not shown). Although PR recruitment to the CTSD promoter was not as robust as ER recruitment, the PR antagonist onapristone diminished estradiol-induced ER binding to the CTSD promoter ( Figure 4e ) and blocked estradiol-induced CTSD mRNA expression ( Figure 4f ) in MCF7L (PR high) cells. These studies further indicate that unliganded PR-B facilitates ER in the regulation of select estradiol-induced genes.
Unliganded PR-B facilitates phosphorylation of specific ER residues in the presence of estradiol or growth factors Previous reports demonstrated that PR-B and ER interact with c-Src as part of tyrosine kinase-associated signaling complexes that function to initiate rapid activation of downstream kinase pathways in response to steroid hormones. 6, 19 One function of SRcontaining rapid signaling complexes is to ensure appropriate phosphorylation of ligand-bound steroid hormone receptors that in turn regulate SR-dependent genomic events. 8, 31 To examine whether PR-B regulates ER phosphorylation, MCF7 cells expressing vector or PR-B were stimulated with estradiol for 1 h before WB with phospho-specific antibodies. IGF-1 treatment was included as a positive control for ER Ser167 phosphorylation. 26 1 and 4) . In addition, this site was appreciably phosphorylated in response to both estradiol and IGF1 (lanes 5 and 6). These data suggest that in the absence of added progestin, PR-B expression serves to increase the ability of estradiol or growth factors (IGF1) to initiate ER-specific phosphorylation events, perhaps via scaffolding of localized cytoplasmic or membrane-associated signaling complexes. PELP1 is part of ER/PR-B-containing transcriptional complex and is recruited to the CTSD promoter Estradiol-bound ER participates in cytoplasmic signaling complexes that include protein kinases (c-Src, phosphoinositide 3-kinase (PI3K)), growth factor receptors (IGF1R, EGFR) and scaffolding molecules (PELP-1 (MNAR)). 18, 20, 32, 33 PELP1 functions to modulate ER activity by acting as a scaffolding molecule for effective cytoplasmic signaling and as an ER transcriptional coactivator in the nucleus. 32 We speculated that PELP1 might enhance local kinase signaling (that is, ER phosphorylation). To determine whether PR-B participates in a signaling complex with ER and PELP1, we performed co-IP assays in MCF7 cells transiently transfected with PR-B and treated cells for 10 min with vehicle, estradiol or IGF-1. PR-specific immunoprecipitates, but not IgG controls, contained abundant PELP1 and low levels of estradiolinduced IGF1R (Figure 5b ). IGF1R and ER were also weakly detected in PELP1 immunoprecipitates from PR-B-expressing MCF7 cells (Supplementary Figure S6A ). Co-immunoprecipitation of ER and PR, published recently, 14 was confirmed in our system (not shown). In addition, PELP1, ER and PR displayed robust binding to the CTSD distal promoter in response to estradiol treatment but not vehicle treatment (Figure 5c ). Interestingly, we also consistently detected weak recruitment of IGF1R to the same region of the CTSD promoter. However, this signaling complex (ER, PR, PELP1 and IGF1R) was not detected on the TFF1 promoter (not shown). These data suggest that cytoplasmic signaling complexes containing ER, PR, PELP1, and IGF1R appear to directly participate in CTSD gene regulation as part of transcriptional complexes associated with chromatin.
IGF1R-and AKT-dependent signaling events are required for CTSD regulation Previous findings have shown that cytoplasmic PELP1 is an enhancer of both mitogen-activated protein kinase and AKT signaling, leading to increased ER phosphorylation on Ser167 and Ser118 and enhanced transcriptional activity. 34 Using a previously characterized DNLS PELP1 mutant that is localized primarily to the cytoplasm, 34 we found that CTSD mRNA expression was higher in cells expressing cytoplasmic DNLS PELP1 than in cells expressing wt PELP1 or cells expressing vector alone (Supplementary Figure S6B) . These data indicate that PELP1-dependent signaling (that is, heightened rapid signaling events) may enhance specific transcriptional responses mediated by ER-, PR-and PELP1containing complexes.
To determine whether PELP1-associated kinase activities are required for estradiol-induced CTSD expression, PR-B þ MCF7 cells were pretreated with inhibitors of IGF1R (AEW541), PI3K (LY-294002), mitogen-activated protein kinase (U0126) and c-Src (PP2). Estradiol-mediated activation of CTSD expression was then examined by qRT-PCR. None of these kinase inhibitors affected basal CTSD mRNA expression in PR-B þ MCF7 cells. PI3K or IGF1R inhibition blocked estradiol-induced CTSD expression ( Figure 5d ). In addition, IGF1R inhibition specifically blocked phosphorylation of ER Ser167 but not Ser118 (inset). In contrast, neither PI3K nor IGF1R inhibition affected estradiol-mediated TFF1 expression ( Figure 5d ). Mitogen-activated protein kinase inhibition with U0126 blocked estradiol-induced CTSD and TFF1 expression (not shown). Surprisingly, c-Src inhibition with PP2 did not significantly alter estradiol-induced CTSD or TFF1 expression, but it did inhibit CCND1 expression, a Src-dependent (positive control) gene (not shown). 35 In ChIP assays, IGF1R inhibition with AEW541 blocked estradiol-induced ER binding to the CTSD promoter; however, it did not affect estradiol-induced ER recruitment to the TFF1 promoter ( Figure 5e ). Taken together, these data support a role for ER/PR-B/PELP1 complexes in the activation of IGF1R and downstream PI3K/AKT signaling in the regulation of CTSD expression.
Dual PR and IGF1R blockade inhibits growth of tamoxifen-resistant breast cancer cells As shown above, blockade of either PR or IGF1R partially reduced estradiol-induced ER binding to the CTSD promoter and blocked CTSD mRNA expression. To determine the effect of dual blockade of PR and IGF1R, we performed soft agar assays in tamoxifensensitive (MCF7L) and -resistant (MCF7 1GX) cell variants. PR þ / IGF1R þ tamoxifen-resistant MCF7 1GX cells were engineered to overexpress RAF1 and passaged once as xenografts in mice. 36 Estradiol-induced colony formation was lower among MCF7L cells treated with onapristone and AEW541 than among cells treated with either agent alone (Figure 6a ). In the presence of tamoxifen, estradiol-treated MCF7 1GX cells exhibited robust colony formation; however, onapristone significantly decreased basal and estradiol-induced growth in soft agar (Figure 6b ). Importantly, estradiol-induced colony formation was completely blocked among MCF7 1GX cells treated with onapristone and AEW541 ( Figure 6c ). These data suggest that PR-B and IGF1R expression alter ER transcriptional programs to enhance breast cancer growth even in the context of tamoxifen resistance, perhaps by resensitizing cells to tamoxifen.
ER/PR/PELP1 complexes are detectable in human breast tumors
To determine whether the ER/PR/PELP1 signaling complex is present in breast cancer in vivo, we obtained human tumor samples and performed co-IP studies. Nine tumor samples, clinically determined to be ER þ /PR þ , expressed PELP1, PR, ER and actin (loading control) in WBs (Figure 7a ). Pull down of PELP1 revealed that PELP1 had a strong association with ER and a variable, yet persistent, association with PR. In addition, ER and PELP1 co-immunoprecipitated with PR in breast tumors, and PELP1 and PR co-immunoprecipitated with ER (not shown). Taken together, these data demonstrate that ER/PR/PELP1 form complexes in human breast cancers, the consequence of which is likely more aggressive proliferative responses to estrogens.
DISCUSSION
The classical definition of PR function is that the receptor is a ligand-activated transcription factor whose promoter selection is driven by rapid cytoplasmic phosphorylation events. 8 Herein, we extend this definition by showing that unliganded PR-B acts as a molecular scaffold for the formation of an ER/PELP1-containing transcription complex at newly defined ER/PR-B target genes. We found that, in the absence of added progestin, the PR-B isoform activated a subset of ER target genes in estradiol-mediated pathways to enhance breast cancer cell proliferation and anchorage-independent growth in multiple cell line models (MCF7, T47D and BT474). In this context, PR-B associated with ER and PELP1 in vitro and in vivo to form a transcriptional complex on select ER target genes, including CTSD. The ER/PR-B/PELP1 complex facilitated the phosphorylation of specific ER sites and activation of IGF1R downstream PI3K/AKT signaling in the regulation of CTSD. We also detected IGF1R at the same region of the CTSD promoter. Inhibition of IGF1R, PR or both blocked estradiol-dependent breast cancer cell proliferation. Importantly, our gene profiling studies indicated that PR-B crosstalk with ER results in more aggressive proliferative responses to estrogens and shifts the ER transcriptome toward the luminal-B phenotype, which is more likely to become tamoxifen resistant. Taken together, our data support a model (Figure 7b ) in which PR-B/ER/PELP1 complexes formed at, or near, the membrane with growth factor receptors (that is, IGF1R) are capable of initiating signaling events (that is, ER phosphorylation) that direct these complexes to specific promoters (that is, CTSD) and thereby activate particular gene sets and their biological programs. Novel ER/PR/PELP1 target genes may provide useful biomarkers for selection of patients likely to respond to antagonism of components of this transcriptional complex or its related signaling pathways.
PR-B DNA-binding domain was required for ER recruitment to target genes Our study shows that unliganded PR-B facilitates estradiol-induced ER interactions with kinases (for example, IGF1R, AKT), perhaps partly because of increased PR-B-driven IRS1 expression. 37 However, the specific function of unliganded PR-B in the ER/PELP1/IGF1R transcriptional complex is likely multifold. We found that the PR-B DNA-binding domain was required for ER recruitment to the CTSD promoter. Direct PR binding to estrogen response element-containing DNA enhancer regions has been reported, 38 although it is also possible that PR-B interacts with a progesterone response element located on a distant region of DNA that loops back to the CTSD region and thereby brings together regulatory regions across large expanses of DNA. 39 Related to this idea, we identified numerous progesterone response element half-sites in close proximity to the CTSD distal ERE, but PR-B recruitment to these sites was not specifically detected in our ChIP assays (not shown). Notably, the ER/PR cooperative mechanism described herein appears distinct from previous descriptions of ER/PR cross-talk upon stimulation of breast cancer cells with progestin. 14 In our study, focused on ligand-independent PR actions, ChIP assays failed to detect ER/PR/ PELP1 complexes in association with either the MYC or CCND1 genes in response to estradiol (not shown).
IGF1R/PI3K pathway contributes to estradiol-induced, ER/PR-Bmediated breast cancer growth ER/PR/PELP1-mediated activation of growth-promoting transcriptional programs described herein required IGF1R and PI3K/AKT activation. These findings underscore the interest in PI3K as an attractive target for endocrine-resistant patients. 40 Indeed, activating mutations in PI3K or AKT occur in up to 25% of breast cancers. 41 In addition, phosphorylation of Ser167, the AKT site on ER, reduces sensitivity to tamoxifen in vitro. 42, 43 Similarly, hyperactive IGF signaling is associated with resistance to endocrine therapies. 44 Notably, blockade of IGF1R with dalotuzumab significantly decreases estradiol-stimulated growth in MCF7L (PR þ ) xenografts. 45 We found that the combination of AEW541 and onapristone completely abolished estradiol-dependent soft agar colony formation in similar MCF7L and tamoxifen-resistant MCF7 1GX cells. However, even though onapristone blocks PRcontaining transcriptional complexes, it leaves upstream (AKT) signaling intact. These findings suggest that combining IGF1R and PR antagonists may provide a means to block endocrine-resistant, ER þ /PR þ tumors via targeting these distinct but highly cooperative pathways.
Breast cancer therapy and ER/PR cross-talk As a classical ER target gene, PR expression is used as a clinical marker of functional ER in breast tumors and thus predicts the likelihood of effective response to ER-targeted therapies. Our data linking heightened estrogen sensitivity to PR scaffolding activity lend additional mechanistic support to these long-held clinical findings. Indeed, our studies underscore the need to consider PR as an active member of ER-containing transcriptional complexes. Interestingly, clinical assessment of PR expression by immunohistochemistry in breast tumors does not distinguish between PR-A and PR-B isoforms. PR-A expression is highly estrogen-dependent, whereas PR-B expression is also regulated by other factors. 46 Notably, the scaffolding activity of PR-B described herein occurs in the absence of added progestin, and ER/PR/PELP1 target genes are unresponsive to added progestin. These genes clearly contribute to breast cancer growth and survival phenotypes. We were surprised that both luminal-B-and tamoxifen-resistant gene sets were enriched in estradiol-treated MCF7 cells expressing PR-B relative to PR-null cells. Although more studies are needed, these provocative data suggest that in the presence of estrogen, PR-B may in fact be required for transition of luminal-A breast cancer cells to the luminal-B subtype.
In sum, inclusion of PR-targeted therapies as part of the modern endocrine arsenal seems warranted and timely. Notably, over half of acquired endocrine-resistant tumors retain PR expression. 47, 48 Furthermore, PR activates many of the same genes as ER, 7 and PR is a major driver of proliferative and prosurvival pathways in the breast and in breast cancer. 8 Herein, we show that PR-B contributes to estrogen responsiveness via direct ER/PELP1 cross-talk at classical estrogen-dependent genes. Thus, combination treatment with both PR-and ER-targeted therapies may provide significant clinical benefit. Indeed, in rat models, additive effects of tamoxifen and onapristone were observed in mammary cancers induced by DMBA or MNU (reviewed in Lanari et al. 49 ). In addition, onapristone (and to a lesser extent RU486) inhibited tumor growth and estrogen stimulation in the MXT mouse model of breast cancer. 49 Similarly, treatment of MCF7 and T47D cells with either tamoxifen or RU486 blocked estrogen-mediated cell proliferation. 49 It is thus tempting to speculate that PR-B in PELP1/ER complexes may function to compensate for ER inhibition in tumors that progress under estrogen-or ER-blocking therapies. As such, we conclude that antiprogestins, perhaps given early as intermittent or cyclical treatments, in combination with current endocrine therapies may prevent or delay endocrine failure in patients with luminal tumors expressing novel ER/PR-B target gene biomarkers.
MATERIALS AND METHODS
Cell lines and reagents T47D-Y (PR-null) and MCF7 (PR-low) 19 cells were stably transfected with pSG5 or pSG5-PR-B and pSV-Neo or pIRES or pIRES-PR-B using FuGENE reagent (Thermo Fisher Scientific, Waltham, MA, USA) to generate multiple vector-matched clones. Cells were cultured as described previously. 12, 19 Additional MCF7 cells were obtained from ATCC (PR-A/B þ ), cultured as indicated, and stably infected with retrovirus expressing LXSN, LXSN-wtPELP1 or LXSN-DNLS PELP1. 34 MCF7C4-12 (PR-null), MCF7L (PR-A/B þ ), BT474 (PR-A/B þ ) and MCF7 1GX (PR-A/B þ ) cells were cultured as described, 12, 26, 36, 50 and MCF7L PR knockdown cells were generated using lentivirus shRNAs targeting PR (five sequences) or green fluorescent protein in pLKO (Thermo Fisher Scientific).
Cells were treated with estradiol (1 nM), tamoxifen (100 nM) and ICI 182 780 (1 mM) obtained from Sigma-Aldrich (St Louis, MO, USA); LY-294002 (10 mM), U0126 (10 mM) and PP2 (10 mM) obtained from Calbiochem (Darmstadt, Germany); R5020 (10 nM) purchased from NEN Life Science Products (Boston, MA, USA); and IGF1 (5 nM) from GroPep Bioreagents (Thebarton, Adelaide, South Australia).
Proliferation assays
MTT and soft agar assays were performed as described previously (with three biological replicates of each condition per experiment) and results presented are representative of two to five experimental repeats. 12, 18 Media was changed every other day in soft agar experiments performed in MCF7L, MCF7 1Gx, and BT474 cells. Student's t-test was performed to determine statistical significance between treatment groups in each experiment. WB and IP assays WB and co-IPs were performed as described previously. 12 The following specific antibodies were used: PR-A and PR-B ab-8 (Thermo Fisher Scientific), PELP1 (Bethyl Laboratories, Montgomery, TX, USA), PR-A and PR-B H190, IGF1Rb, ER (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), actin (Sigma-Aldrich), ER phospho-167, ER phospho-118 and Erk1/2 (Cell Signaling, Beverly, MA, USA).
qRT-PCR
RNA was isolated from cells in triplicate wells treated with ethanol (vehicle) or estradiol (1 nM) for 24 h using TriReagent (Roche, Basel, Switzerland). Data shown are representative of two to nine replicates of each qPCR experiment that was performed as described previously. 12 Student's t-tests were performed to determine statistical significance between treatment groups in each experiment.
ChIP assay
ChIP assays were performed using ChIP-IT Express Kits (ActiveMotif, Carlsbad, CA, USA), according to the manufacturer's protocol as described previously, 12 and antibodies specific for PR (ab-8) and ER (Santa Cruz Biotechnologies). Briefly, MCF7 (7 Â 10 6 ) or T47D (15 Â 10 6 ) cells were plated in 150 mm dishes, starved in unsupplemented phenol red-free Improved modified essential medium (24 h) and treated for 40 min or 1 h with ethanol or estradiol. Relative recruitment was determined by qPCR of
